Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04437030
Other study ID # MSOT HNC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 9, 2020
Est. completion date July 1, 2023

Study information

Verified date January 2024
Source University Hospital Heidelberg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multispectral photoacoustic imaging enables the measurement of the optical absorption of various tissue components or exogenous contrast agents in vivo. The dominant, near infrared absorbing chromophores in human tissue are oxy- and deoxyhemoglobin followed by collagen, melanin and lipids. The multispectral measurement of the absorption of hemoglobin shows changes in blood oxygen saturation and blood volume. The high resolution of photoacoustic imaging also enables the vascular structure to be displayed. The aim of this exploratory study is to generate hypotheses by applying photoacoustic imaging to the field of head and neck tumor therapy. The next step is to investigate whether and how photoacoustic imaging can help improve diagnostics and better planning of treatments in the future. In particular, the differences between normal and tumor tissue and the changes in the tissue due to radiation therapy using photoacoustic imaging are examined. In the quantitative analysis of the images, measured chromophores, primarily oxygen saturation, blood volume and collagen concentrations at different measuring points are used in the course of the therapy.


Description:

Multispectral photoacoustics enable non-invasive, inexpensive and dose-free real-time imaging of light-absorbing molecules (absorbers), e.g. Deoxyhemoglobin and oxygenated hemoglobin in human tissue. This allows blood oxygen saturation (sO2) to be determined at depths of up to several centimeters. Measurements of correlates to blood volume and collagen concentration are also made possible. In photoacoustic imaging, the tissue to be examined is irradiated with nanosecond short, near-infrared (650 - 1300nm) laser pulses. If laser light is locally absorbed by a tissue structure, it expands thermoelastically, which triggers an ultrasonic pressure wave, which is measured with the aid of an ultrasonic head. The initial pressure distribution and thus the absorption in the tissue can then be reconstructed. Since different molecules show distinct absorption behavior depending on the wavelength in the near infrared, by acquiring several wavelengths it is possible to estimate which absorbers are in which concentration in a tissue structure. The effectiveness and tolerability of modern high-precision radiation therapy for head and neck tumors largely depends on the quality of the imaging. The potential diagnostic benefits of photoacoustics in the radiotherapy of patients with head and neck tumors principally concern the target volume definition, the implementation of image-guided, adaptive radiotherapy and imaging tumor follow-up as well as the early detection of tumors. Multispectral photoacoustics primarily enable the analysis of tumor hypoxia, which has been associated several times with increased radio resistance and an unfavorable prognosis. In addition, other factors, e.g. the blood volume and the collagen content in the tissue are analyzed.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 1, 2023
Est. primary completion date January 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Willingness and ability to participate 2. sufficient knowledge of German to understand the patient / subject information and the declaration of consent, 3. tumor disease to be treated by radiotherapy in the neck and neck area, 4. Completed wound healing after operative interventions in the head and neck area, 5. The patient's consent and written consent, 6. the patient's ability to assess the nature and scope as well as possible consequences of the clinical study, 8. Age = 18 years. Requirement 3 does not apply to the control group of healthy subjects Exclusion Criteria: - Pre-radiation in the head and neck area - Inadequate regression of toxicities from previous therapies - Indications that the participant is unlikely to adhere to the study protocol (e.g. lack of compliance) - Missing written declaration of consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MSOT Acuity Echo device
The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.

Locations

Country Name City State
Germany University Hopsital Heidelberg Heidelberg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Heidelberg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary diagnostic feasibility of photoacoustic imaging: Oxygen Saturation Measurement of Oxygen Saturation in the tumor tissue previouse to Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: Oxygen Saturation Measurement of Oxygen Saturation in the tumor tissue 3 weeks after Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: Oxygen Saturation Measurement of Oxygen Saturation in the tumor tissue 3 month after Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: blood volume blood volume previouse to Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: blood volume blood volume 3 weeks after Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: blood volume blood volume 3 month after Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: blood volume amount of collagen in the tumor tissue previouse to Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: amount of collagen in the tumor tissue amount of collagen in the tumor tissue 3 weeks after Radiotherapy start
Primary diagnostic feasibility of photoacoustic imaging: amount of collagen in the tumor tissue amount of collagen in the tumor tissue 3 month after Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue Differences of Oxygen saturation previouse to Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue Differences of Oxygen saturation 3 weeks after Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue Differences of Oxygen saturation 3 month after Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue blood volume previouse to Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue blood volume 3 weeks after Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue blood volume 3 month after Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue amount of collagen previouse to Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue amount of collagen 3 weeks after Radiotherapy start
Secondary Analysis of Tumor tissue and normal tissue amount of collagen 3 month after Radiotherapy start
Secondary multimodal information about tissue morphology Registration of photoaccustic and MRI/CT Imaging previouse to Radiotherapy start
Secondary multimodal information about tissue function Registration of photoaccustic and MRI/CT Imaging 3 weeks after Radiotherapy start
Secondary multimodal information about tissue function Registration of photoaccustic and MRI/CT Imaging 3 month after Radiotherapy start
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2